RESEARCH ARTICLE

The Small Molecule DAM Inhibitor, Pyrimidinedione, Disrupts *Streptococcus pneumoniae* Biofilm Growth *In Vitro*

Mukesh Kumar Yadav1,2, Yoon Young Go1, Sung-Won Chae1, Jae-Jun Song1*

1 Department of Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine, Seoul, South Korea, 2 Institute for Medical Device Clinical Trials, Korea University College of Medicine, Seoul, South Korea

* jjsong23@gmail.com

Abstract

*Streptococcus pneumoniae* persist in the human nasopharynx within organized biofilms. However, expansion to other tissues may cause severe infections such as pneumonia, otitis media, bacteremia, and meningitis, especially in children and the elderly. Bacteria within biofilms possess increased tolerance to antibiotics and are able to resist host defense systems. Bacteria within biofilms exhibit different physiology, metabolism, and gene expression profiles than planktonic cells. These differences underscore the need to identify alternative therapeutic targets and novel antimicrobial compounds that are effective against pneumococcal biofilms. In bacteria, DNA adenine methyltransferase (Dam) alters pathogenic gene expression and catalyzes the methylation of adenine in the DNA duplex and of macromolecules during the activated methyl cycle (AMC). In pneumococci, AMC is involved in the biosynthesis of quorum sensing molecules that regulate competence and biofilm formation. In this study, we examine the effect of a small molecule Dam inhibitor, pyrimidinedione, on *Streptococcus pneumoniae* biofilm formation and evaluate the changes in global gene expression within biofilms via microarray analysis. The effects of pyrimidinedione on *in vitro* biofilms were studied using a static microtiter plate assay, and the architecture of the biofilms was viewed using confocal and scanning electron microscopy. The cytotoxicity of pyrimidinedione was tested on a human middle ear epithelium cell line by CCK-8. *In situ* oligonucleotide microarray was used to compare the global gene expression of *Streptococcus pneumoniae* D39 within biofilms grown in the presence and absence of pyrimidinedione. Real-time RT-PCR was used to study gene expression. Pyrimidinedione inhibits pneumococcal biofilm growth *in vitro* in a concentration-dependent manner, but it does not inhibit planktonic cell growth. Confocal microscopy analysis revealed the absence of organized biofilms, where cell-clumps were scattered and attached to the bottom of the plate when cells were grown in the presence of pyrimidinedione. Scanning electron microscopy analysis demonstrated the absence of an extracellular polysaccharide matrix in pyrimidinedione-grown biofilms compared to control-biofilms. Pyrimidinedione also significantly inhibited MRSA, MSSA, and *Staphylococcus epidermidis* biofilm growth *in vitro*. Furthermore, pyrimidinedione does not exhibit eukaryotic cell toxicity. In a microarray analysis, 56 genes...
were significantly up-regulated and 204 genes were significantly down-regulated. Genes involved in galactose metabolism were exclusively up-regulated in pyrimidinedione-grown biofilms. Genes related to DNA replication, cell division and the cell cycle, pathogenesis, phosphate-specific transport, signal transduction, fatty acid biosynthesis, protein folding, homeostasis, competence, and biofilm formation were down regulated in pyrimidinedione-grown biofilms. This study demonstrated that the small molecule Dam inhibitor, pyrimidinedione, inhibits pneumococcal biofilm growth in vitro at concentrations that do not inhibit planktonic cell growth and down regulates important metabolic-, virulence-, competence-, and biofilm-related genes. The identification of a small molecule (pyrimidinedione) with S. pneumoniae biofilm-inhibiting capabilities has potential for the development of new compounds that prevent biofilm formation.

Introduction

Streptococcus pneumoniae (S. pneumoniae) is an important human pathogen. It causes severe and invasive infections, such as pneumonia, septicemia, otitis media, and meningitis, especially in children, the elderly, and immuno-compromised patients [1,2,3]. S. pneumoniae initially colonize the nasopharynx and may persist for months without causing illness, forming specialized structures called biofilms [4,5]. Pneumococci from these biofilms can migrate to other sterile anatomical sites, causing severe biofilm-associated infections such as pneumonia and otitis media [6,7,8]. The planktonic bacteria from these biofilm-associated infections can migrate to other sterile sites, such as the blood stream, causing bacteremia, or to the brain, causing meningitis [9,10,11].

A biofilm is defined as a thin layer of bacteria that adhere to each other and to a living tissue or inert surfaces. These bacteria are surrounded by a self-produced polymeric matrix composed of polysaccharides, proteins, and nucleic acids [12]. Bacteria within biofilms possess increased tolerance to antibiotics and are able to resist host defense systems [13,14]. S. pneumoniae biofilms show increased resistance to common antibiotics, such as penicillin, tetracycline, rifampicin, amoxicillin, erythromycin, clindamycin, levofloxacin, and gentamicin both in vivo and in vitro [15,16,17]. Bacteria within biofilms exhibit altered physiology, metabolism, and gene expression profiles compared to free-floating planktonic cells [18]. Therefore, existing antimicrobial compounds mainly developed to target planktonic bacteria may not be as effective against biofilms. Moreover, the emergence of antibiotic resistant pneumococcal strains necessitates the identification of alternative drug targets and new antimicrobial compounds that could be effective against pneumococcal biofilms. Effective anti-biofilm strategies could inhibit initial bacterial attachment and colonization, interfere with signaling pathways important for biofilm development, or disrupt the biofilm matrix [19,20,21].

Bacterial DNA methyltransferases are generally associated with restriction-modification systems, with the exception of DNA adenine methyltransferase (Dam) and cell cycle-regulated methyltransferase (CcrM) [22]. In bacteria, Dam alters the expression of pathogenic genes involved in several cellular activities, including mismatch repair, initiation of chromosomal replication, DNA segregation, and transposition [23,24]. In bacteria the Dam enzyme catalyzes a methyl group transfer from S-adenosyl-L-methionine (SAM) to the N⁶ position of adenine in duplex DNA (Fig 1A). This adenine methylation is unique in bacteria. Therefore, these bacterial enzymes represent excellent antimicrobial target candidates. Moreover, SAM-mediated methylation is an important process in pneumococci, leading to the methylation of DNA and
macromolecules, as well as the biosynthesis of quorum sensing (QS) molecules and secondary metabolites, such as polyamine, that play roles in biofilm formation [25,26]. Our previous study showed that 5-azacytidine, a hypo-methylating compound, and sinefungin, a SAM analogue, inhibit *S. pneumoniae* biofilm growth [27,28]. However, the effect of Dam inhibitor small molecule on pneumococcal biofilm formation has not been studied.

In the present study, we examine the effect of a small molecule Dam inhibitor, pyrimidinedione, on *S. pneumoniae* biofilms, evaluating changes in global gene expression via microarray analysis. The small molecule pyrimidinedione, 1-(4-bromophenyl)-5-(2-furylmethylene)-3-phenyl-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione, was reported to be an effective bacterial Dam and CcrM inhibitor. It binds to the ternary enzyme:DNA:AdoMet complex and prevents Dam activity [29].

Our results demonstrated that pyrimidinedione inhibited pneumococcal biofilm growth *in vitro* at concentrations that did not inhibit planktonic cell growth, and it down-regulated the expression of important metabolic-, virulence-, competence-, and biofilm-related genes. Pyrimidinedione is also effective against MSSA, MRSA, and *Staphylococcus epidermidis* biofilms *in vitro*, and it is not cytotoxic to eukaryotic cells. The identification of a small molecule (pyrimidinedione) with *S. pneumoniae* biofilm-inhibiting capabilities has potential for the development of new compounds that prevent biofilm formation.

**Materials and Methods**

**Ethics statement**

The experimental protocol was approved by the Institutional Review Board of Korea University, Guro Hospital, Seoul, South Korea. The human middle ear epithelium cell (HMEEC) line used in this study was kindly provided by Dr. David J. Lim (House Ear Institute, LA, USA). Pre-made blood agar plates (BAPs) containing 5% v/v sheep blood were purchased from Shin Yang chemicals Co., Ltd. (Seoul, Korea).
Bacterial strains and culture conditions

*S. pneumoniae* serotype 2 (D39 strain; NCTC 7466) was purchased from Health Protection Agency Culture Collections (HPA, Salisbury, UK), serotype 3 (ATCC strain 6303) and serotype 19 (ATCC strain 49619) were purchased from ATCC (Manassas, VA, USA). *S. pneumoniae* serotype 11 (strain 7101975) was obtained from the infectious disease department of Korea University Medical Center, Guro Hospital, Seoul. Bacteria were routinely grown in tryptic soy broth (TSB; BD Difco; Detroit, MI, USA) or on BAPs supplemented with 5% v/v sheep blood at 37°C in 5% atmospheric CO₂. Five methicillin-resistant *Staphylococcus aureus* (MRSA) strains (CCARM 3108, CCARM 3807, CCARM 3912, CCARM 3903, and CCARM 3967) were purchased from Culture Collection of Antimicrobial Resistant Microbes (CCARM; Seoul, Korea). Methicillin-sensitive *Staphylococcus aureus* (MSSA, ATCC 29213) and *Staphylococcus epidermidis* (ATCC 35984) were purchased from ATCC. The small molecule inhibitor (here called pyrimidinedione) 1-(4 bromophenyl)-5-(2-furylmethylene)-3-phenyl-2-thioxodihydro-4, 6 (1H,5H)-pyrimidinedione, was purchased from ChemBridge, USA (catalogue number sc5309471; Fig 1B). A stock solution of pyrimidinedione was prepared in DMSO.

Growth curve of *S. pneumoniae* D39 with pyrimidinedione

Cultures of *S. pneumoniae* D39 were grown in the presence of 1 and 10 μM/ml concentrations of pyrimidinedione in a time course experiment. The cell suspensions were incubated at 37°C in 5% CO₂, and the optical density at 600nm (OD₆₀₀) was measured with a spectrophotometer (SpectraMax plus, Molecular Devices, Sunnyvale, CA, USA) at different time points (1, 2, 3, 4, 5, 6, 7, 8, 9 and 10h). The experiments were performed in replicates of five and were repeated three times to obtain statistical significance.

Effect of pyrimidinedione on *in vitro* biofilm growth

*S. pneumoniae* and *Staphylococcus* biofilm formation experiments were carried out using a static model in 96-well or 24-well microtiter plates [18,30]. Briefly, bacterial colonies grown overnight on blood agar were scraped and seeded in broth (TSB medium) and further grown until mid-logarithmic phase (1×10⁸ cfu/ml). Bacterial cells were diluted 1:1000 in fresh broth, and 200 μl or 1 ml cell suspension was used to inoculate a 96- or 24-well microtiter plate. Plates were then incubated at 37°C in 5% CO₂. Pyrimidinedione was added to each plate, as indicated. Control samples did not contain any supplement, and DMSO-control samples contained 0.01% DMSO (final concentration). After incubation, the medium and planktonic cells were discarded, and the plates were washed three times with sterile PBS. The plates were air dried for 15 min and stained with crystal violet (CV; 0.1%) for 15 min. The CV stain was removed and the plates were washed again. The stained biofilm was dissolved in 95% ethanol, and the OD₅₇₀ was measured in an automatic spectrophotometer. All experiments were performed with five replicates, and the average was calculated. To quantify the bacteria within biofilms, plates inoculated as described above were washed, and adherent biofilms were dissolved in sterile water via sonication for 10 s. One hundred micro-liter samples were serially diluted, plated on blood agar plates, and incubated at 37°C in 5% CO₂ for 24 h. After incubation, bacterial colonies were counted and cfu/ml was determined. Planktonic cells (cells in the biofilm supernatant) were counted in a similar manner.

Effect of pyrimidinedione concentration on biofilm growth

*S. pneumoniae* (serotypes 2, 3, 19, and 11) biofilms were grown in different concentrations of pyrimidinedione (0.5–10 μM/ml) for 15 h, as previously described. Biofilm biomass was
measured using the CV-microtiter plate method. Cfu counts of bacteria within biofilms (D39 strain) were conducted as described above. The percent decrease in biofilm biomass was calculated by subtracting the biomass of DMSO-control samples. The half-maximal effective concentration (EC50) of pyrimidinedione was determined as the concentration corresponding to 50% of the maximum biofilm inhibition with respect to DMSO-control biofilms. At each pyrimidinedione concentration, cells suspended within the biofilm supernatant were collected and analyzed. Bacterial growth was detected by measuring optical density at 600 nm (OD600), and cfu of planktonic bacteria in the biofilm supernatant of D39 were counted.

To determine whether the biofilm-inhibiting effects of pyrimidinedione extended beyond *S. pneumoniae*, pyrimidinedione was tested on other biofilm-forming microbial pathogens, such as MSSA, MRSA, and *S. epidermidis*. *Staphylococcus* 24 h biofilm assays were carried out in a similar manner as described above, in TSB medium supplied with 1, 5, and 10 μM/ml pyrimidinedione.

**Effect of pyrimidinedione on biofilms grown at different time points**

*In vitro* *S. pneumoniae* biofilm growth varies at different time points. Therefore, we analyzed the effects of pyrimidinedione on *S. pneumoniae* D39 biofilms at different time points *in vitro*. *S. pneumoniae* biofilm was grown at different concentrations of pyrimidinedione [0 (DMSO control), 0.5, 1, 5, and 10 μM/ml] for 5, 10, 15, and 20 h.

**Effect of pyrimidinedione on established biofilms**

To analyze the inhibitory effects of pyrimidinedione on established biofilms, *S. pneumoniae* D39 biofilms were grown for 15 h. These established biofilms were then treated with different concentrations (1−400 μM/ml) of pyrimidinedione and further incubated at 37°C in 5% CO2 for 6 h. The biofilms were washed, and the biofilm biomass was detected by CV-microtiter plate assay.

**Visualization of pneumococcal (D39 strain) biofilm growth by confocal microscopy**

*In vitro* biofilm growth, with and without pyrimidinedione, was analyzed by confocal microscopy. Biofilms were grown on microdiscs for 15 h with 7 μM/ml pyrimidinedione and stained using LIVE/DEAD Biofilm Viability staining kit (Invitrogen). A control sample was grown with 0.01% DMSO (final concentration). Biofilms were examined with a Nikon A1 confocal microscope (Nikon Instruments Inc., NY, USA) using fluorescein (green) and Texas red (red) band pass filter sets. The live bacteria with intact cell membranes appear green, and those with damaged membranes appear red.

**Visualization of biofilm morphology by scanning electron microscopy (SEM)**

Pneumococcal (D39 strain) biofilms grown with 7 μM/ml pyrimidinedione in 24-well tissue culture plates for 15 h were analyzed by SEM. The control sample was grown in 0.01% DMSO. Planktonic cells were removed, and the plates were gently washed twice with sterile PBS (pH 7.4). The samples were pre-fixed for 2 h in a 2% glutaraldehyde and paraformaldehyde solution, followed by 2 h post-fixation in 1% osmic acid. The samples were then treated with a graded series of ethanol (from 60% to 100%), washed three times with t-butyl alcohol, and were then immersed in t-butyl solution at -20°C. The samples were dried in a freeze dryer (ES-2030, Hitachi, Tokyo, Japan) and platinum coated using an IB-5 ion coater (Eiko, Kanagawa,
Japan). The samples were visualized using a S-4700 field emission scanning electron microscope (Hitachi).

Effect of pyrimidinedione on biofilm global gene expression

*In situ* synthesis of oligonucleotide microarrays was used to compare global gene expressions between the *S. pneumoniae* D39 strain within biofilms grown in the presence and absence of pyrimidinedione. Biofilms were grown with 7 μM/ml pyrimidinedione, as described above, in 24-well plates and washed with sterile water. The adherent biofilm cells at the bottom and side of plate were scraped, pelletted, and subjected to lysozyme 100 μl (3 mg/ml) treatment for 4 min. Total RNA was isolated using the RNeasy Total RNA Isolation System Kit (Qiagen, Valencia, CA, USA) following the manufacturer’s protocol. Contaminated genomic DNA was removed on a column by RNAase-free DNase (Qiagen) treatment at 20–25°C for 10 min. RNA was quantified by Nano-Drop, and its integrity was checked by capillary electrophoresis using a Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA, USA).

cRNA probes synthesis and hybridization were performed using a Low Input Quick Amp WT Labeling Kit (Agilent Technologies USA) as per manufacturer’s protocol. Briefly, 100ng total RNA was mixed with WT primer mix and incubated for 10 min at 65°C. A cDNA master mix (0.1M DTT, 5X first strand buffer, RNase-OUT, 10mM dNTP mix, and MMLV-RT) was prepared separately, and mixed with the RNA with WT primers mix and incubated at 40°C for 2 h and thereafter at 70°C for 10min. Transcription of dsDNA was performed by adding the transcription master mix (NTP mix, 4X transcription buffer, 50% PEG, 0.1 M DTT, RNase-Out, T7-RNA polymerase, inorganic pyrophosphatase, and cyanine 5-CTP) to the dsDNA reaction samples and incubating the samples at 40°C for 2 h. Amplified and labeled cRNA was purified on RNase mini columns (Qiagen) and quantified using a spectrophotometer. The cyanine 5-labeled cRNA mix was fragmented by incubating at 60°C for 30 min with 10X blocking agent and 25X fragmentation buffer. The fragmented cRNA were dissolved in 2X hybridization buffer and pipetted on the assembled *Streptococcus pneumoniae* D39 (MYcroarray.com) 6 × 7k Microarray. The hybridization reaction was performed in hybridization oven at 57°C for 17 h and the arrays were washed as per manufacturer’s instructions.

Hybridization images were analyzed with DNA Microarray Scanner (Agilent Technologies) and the data quantification was performed using Agilent Feature Extraction Software version 10.7 (Agilent Technologies). The average fluorescence intensity for each spot was calculated, and the local background was subtracted. All data normalization and the selection of differentially expressed genes were performed using GenoWiz 4.0 (Ocimum Biosolutions, India). Genes were filtered by removing flag-out genes from each experiment. Global normalization was performed. The average normalized signal channel intensities were divided by the average normalized control channel intensities to calculate the average normalization ratio.

Microarray experiments were performed in three biological replicates. Statistical significance was determined by Student’s *t*-test. A *p* value less than 0.05 was considered significant. A 1.4-fold change in each gene, and in each microarray experiment, was considered significant and was included in the final results. The functional annotation (molecular and biological function) and gene ontology of the two sets of differentially expressed genes were determined using the UniPortKB database (http://www.uniport.org/uniport/P0A4M0) and STRING version 9.1. Microarray data were deposited in NCBI’s Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/info/linking.html) and are accessible through GEO Series accession number GSE65339.
Quantification of gene expression by real-time RT-PCR

Microarray gene expression results were confirmed by real-time RT-PCR. Thirteen differentially expressed genes, along with the control gyrB gene, were analyzed by real-time RT-PCR. The primers used are shown in Table 1. cDNA amplification was carried out with real-time PCR in a reaction mixture of 20 μl (total volume). The reaction mixture consisted of 10 μl 2× SYBR Green PCR Master Mix (Roche Applied Science, Indianapolis, IN, USA), 3 pmol of each forward and reverse primers, and 4 μl cDNA. The PCR reaction conditions were as follows: initial denaturation at 95°C for 10 min, followed by 45 cycles of DNA denaturation for 15 s at 95°C, primer annealing for 10 s at 56°C, and extension for 15 s at 72°C; and a final extension step at 72°C for 5 min. To verify that cDNA samples were not contaminated with genomic DNA, a control reaction where no reverse transcriptase was added was included in each RT-PCR experiment. The relative quantification of gene expression was performed using the 2^{−ΔΔCT} method as described elsewhere [31]. Gene expression normalization was performed using a housekeeping gene, gyrB, and the standard condition was a biofilm grown without pyrimidinedione.

Evaluation of pyrimidinedione-mediated eukaryotic cellular cytotoxicity by Cell-Counting Kit (CCK-8)

The cytotoxicity of pyrimidinedione was tested on the human middle ear epithelium cell (HMEEC) line using a CCK-8 kit (Dojindo, MD, USA). HMEECs were kindly provided by Dr.

| Gene name | Primer sequence | Base-pairs |
|-----------|-----------------|------------|
| purC      | F-GACTGCCTTCAACGGTTGCA | 21         |
|           | R-ACACCAGCCGATTTAATT  | 20         |
| capD      | F- AAGCAGGTCTTTGAGGAG  | 20         |
|           | R-AGACAGAAAGCCAAACTCCTA  | 20         |
| adk       | F- AGGGAACTCAAGCGAGAA  | 20         |
|           | R-CAGGAACCAATTCTACCTTG  | 20         |
| lacG-2    | F- ACTAGCTGTTGGCAGTG   | 20         |
| lacT      | F- CAAGCGGAACATCTTTTGA  | 20         |
| galT-1    | F- TGCTCTAAACATCTTTTCG  | 22         |
| cglD      | F- CTGATGCTGCTGAAATCT  | 20         |
| nrdG      | F- CAAAGATGAAAGAGCGAGA  | 20         |
| fabD      | F- GGATGGGACGGGATAT    | 20         |
| dnaK      | F- AAAATCATCGCAAACCCAGA  | 20         |
| pstB      | F- TACCGATGAAAGCGATTTGG  | 20         |
| phoU      | F- GGCCAATTCTGCGAGTAA  | 20         |
| acpP      | F- GGACACGATTCCTTGAGACT  | 20         |

Table 1. List of primers used in this study.
David J. Lim (House Ear Institute, LA, USA) and were maintained in DMEM and BEBM medium (1:1) with required supplements [32,33]. HMEECs (1×10^4 /well) were seeded in 96-well plates and incubated at 37°C overnight in presence of 5% CO_2. After overnight culture, HMEECs were treated with pyrimidinedione (1, 5, or 10 μM/ml) for 24 h in triplicate. Positive and negative control wells were supplemented with 0.01% DMSO (final concentration) or 2% Triton X-100, respectively. After incubation, 10 μl CCK8 solution was added to each well, and the cells were incubated for a further 2–3 h. Mitochondrial dehydrogenase within the cells reduced CCK8 solution to a yellow product called formazan. The amount of formazan produced in the reaction sample is positively correlated with cell viability. Absorbance at 450nm was measured using a microplate reader.

Statistical analysis
Individual experiments were carried out in triplicates or five-replicates, and mean values were calculated. The mean value differences were assessed by Student’s t-test, and the statistical significance was set at a p-value of less than 0.05.

Results
Growth curve of S. pneumoniae supplemented with pyrimidinedione
The planktonic cell growth of S. pneumoniae D39 in the presence of pyrimidinedione (1μM/ml or 10 μM/ml) was not significantly inhibited during the time course experiment. At 6 h incubation, 12% of the cells were inhibited, however, at stationary phase (10 h post-inoculation), planktonic cell growth was not inhibited (Fig 2). This result indicated that pyrimidinedione is partially bacteriostatic, and it has no effect on final bacteria planktonic growth.

Pyrimidinedione inhibits S. pneumoniae (serotype 2, 3, 19 and 11) biofilm growth in vitro
Addition of pyrimidinedione inhibited pneumococcal biofilm growth in vitro. A significant decrease (p<0.05) in biofilm biomass of S. pneumoniae serotypes 2, 3, 19, and 11 were detected in biofilms grown in the presence of pyrimidinedione (Fig 3A). The inhibitory effects of pyrimidinedione was concentration dependent, and the calculated EC_{50} (S. pneumoniae D39) was 1 μM. Addition of 1 μM/ml pyrimidinedione significantly decreased S. pneumoniae D39 biofilm biomass by 54% (p< 0.05, Fig 3A) and cfu counts by 83% (p< 0.05, Fig 3B) in comparison to DMSO-control biofilms. However, the planktonic cell growth of S. pneumoniae serotypes 2, 3, 19, and 11 in the presence of pyrimidinedione was not significantly decreased (Fig 2). Similarly, no significant decrease in planktonic bacterial cfu counts was detected in the D39 strain (Fig 3D). This result indicated that pyrimidinedione significantly inhibits biofilm growth but has no effect on planktonic growth. The inhibitory effect of pyrimidinedione was significant in all S. pneumoniae serotypes tested, indicating that the inhibitory effect of pyrimidinedione was independent of serotypes, and the application of this molecule could be extent to other serotypes biofilms as well. Pyrimidinedione significantly inhibited in vitro MSSA, MRSA, and S. epidermidis biofilm growth in a dose-dependent manner, similar to that observed in pneumococci (Fig 4). S. epidermidis, MSSA 29213 and MRSA CCARM 3903 are strong biofilm producing strains. 1 μM/ml concentration of pyrimidinedione significantly (p< 0.05) decreased biofilm biomass of S. epidermidis, MSSA 29213 and MRSA 3903 by 50, 55 and 53% respectively. This indicates that pyrimidinedione is equally effective against both antibiotic resistance and sensitive strong biofilm producing staphylococcus.
Pyrimidinedione inhibits *S. pneumoniae* D39 biofilm growth at both early and late stages

The growth of biofilms under different pyrimidinedione conditions was inhibited at each time point analyzed. A dose-dependent decrease in biofilm biomass was detected in biofilms grown with pyrimidinedione compared to DMSO-control samples (Fig 5). In the DMSO control, there was an increase in biofilm growth at 5 h of incubation, maximal growth occurred at 10 h of incubation, and then biofilm growth declined. A 70% decrease in biofilm growth was observed with the addition of 5 μM pyrimidinedione at 10 h of incubation. These results indicated that pyrimidinedione is an effective inhibitor of *S. pneumoniae* biofilm growth *in vitro* at both early (5 h) and late (20 h) stages.
Pyrimidinedione has no effect on established biofilm biomass

Established *S. pneumoniae* biofilms were treated with different concentrations of pyrimidinedione. Biofilm quantification by CV-microtiter plate assay demonstrated no significant decrease in biofilm biomass following a 6-h treatment with pyrimidinedione (Fig 6A). There was also no difference observed in cfu counts between control and pyrimidinedione-treated biofilms (Fig 6B). This indicates that pyrimidinedione is unable to dismantle biofilms or kill bacteria within biofilms. Hence, this small molecule cannot eradicate an established biofilm.

Visualization of biofilm growth by confocal microscopy

Confocal microscopy analysis revealed a significant difference in the morphology of biofilms grown in the presence of pyrimidinedione compared to control biofilms (DMSO alone). Control biofilms were compact, thick, and had a well-organized three-dimensional structure (Fig 7A & 7B). In contrast, biofilms grown with pyrimidinedione were thin, the cells were scattered and attached to the bottom of disc, and their three-dimensional structure was not well
organized (Fig 7B & 7D). This strongly suggested that pyrimidinedione inhibits biofilm growth and the formation of organized structures.

Visualization of biofilm morphology by scanning electron microscopy

SEM analysis revealed that control biofilms (DMSO-control) were thick, organized, and heterogeneous with micro-colonies. The cells were surrounded by extracellular matrix and were connected to the bottom of the plate and to each other, forming a three-dimensional organized biofilm structure of significant depth (Fig 8A, 8B, 8C & 8D). The extracellular polysaccharide matrix (EPS) was clearly visible on the cell surface (Fig 8D, arrow). In contrast, pyrimidinedione-exposed biofilms were thin, disorganized, and devoid of micro-colonies. Cells were attached only to the base of the plate, while cell-cell adherence was absent (Fig 8E, 8F, 8G & 8H). The cell surfaces were smooth and devoid of matrix and EPS. These results indicated that in presence of pyrimidinedione, pneumococci were unable to form an organized biofilm.

Effect of pyrimidinedione on biofilm global gene expression

Upon microarray analysis, it was determined that the expression of 56 S. pneumoniae genes was significantly ($p < 0.05$) up-regulated, while expression of 204 genes was significantly ($p < 0.05$) down-regulated in pyrimidinedione-grown biofilms, as compared to controls. Among the 56 up-regulated genes, 22 encoded uncharacterized and hypothetical proteins, and 34 encoded functional proteins (Table 2). Of the 204 down-regulated genes, 45 encoded hypothetical proteins and 159 encoded functional proteins (Table 3). Genes involved in some functional...
protein categories were exclusively down-regulated or up-regulated in pyrimidinedione-grown biofilms (Fig 9).

**Fig 5.** *S. pneumoniae* D39 biofilms grown at different concentrations of pyrimidinedione over time. Biofilm biomass was detected by CV-microtiter plate assay. The results were compared by Student’s *t*-test (* corresponds to *p* < 0.05, ** corresponds to *p* < 0.01). The error bars represent the SD.

doi:10.1371/journal.pone.0139238.g005

**Fig 6.** Effects of pyrimidinedione on established biofilms. Established *S. pneumoniae* D39 biofilms were treated with different concentrations of pyrimidinedione. (A) Biofilm biomasses were measured by CV-microtiter plate assay. (B) Cfu counts of biofilms. The error bars represent the SD.

doi:10.1371/journal.pone.0139238.g006
The functional annotation of the differentially regulated genes revealed that genes involved in galactose metabolism were exclusively up-regulated in pyrimidinedione-grown biofilms. Genes related to DNA replication, cell division and the cell cycle, pathogenesis, phosphate-specific transport, signal transduction, fatty acid biosynthesis, protein folding, homeostasis, competence, and biofilm formation were down-regulated. The fold change values of relative gene expression and predicted protein functions are detailed in Tables 2 and 3.

Nine genes involved in galactose metabolism were significantly up-regulated, while eight genes were down-regulated. Tagatose-6-phosphate pathway genes (lacA, lacB, lacC, lacD, and lacG-2) and Leloir pathway (galT-1 and galE-2) genes were significantly up-regulated (Fig 10). In addition, the lacF2 gene (encoding the PTS system, lactose-specific IIA component) and the lacE2 gene (encoding the PTS system, lactose-specific IIBC components) were also up-regulated. However, the gap (encoding glyceraldehyde-3-phosphate dehydrogenase), eno (encoding phosphoketolase), and pyk (encoding pyruvate kinase) genes involved in glycolysis were down-regulated.

The microarray results detected that expression of 11 genes belonging to the fatty acid synthesis (FAS) locus was significantly down-regulated (more than 1.4-fold) in pneumococcal biofilms grown in the presence of pyrimidinedione. No FAS pathway genes were up-regulated.
The FAS pathway is made up of 13 genes arranged in a single locus that are involved in FAS initiation and product elongation (Fig 11).

Five genes involved in signal transduction were also down-regulated in pyrimidinedione-grown biofilms. Expression of the ciaR and ciaH gene, encoding a DNA-binding response regulator protein and a sensor histidine kinase respectively were down-regulated. These two genes encode the two-component regulatory system CiaH/CiaR, which is involved in the early steps of competence regulation. Expression of the comC gene, encoding the competence-stimulating peptide type 1, essential for pneumococcal competence and biofilm formation, was down-regulated 1.5-fold. Similarly, expressions of the ptsH gene, encoding the phosphocarrier protein HPr, and the SPD_0082 gene, encoding a sensor histidine kinase, were down-regulated 1.6- and 1.4-fold, respectively.

The expression of six virulence protein-encoding genes, ply, SPD_1295 (hemolysin), nrc (SPD_0729), prtA, lytB, and srtA was down-regulated in pyrimidinedione-grown biofilms. The expression of the ply gene was down-regulated 1.5-fold. The SPD_1295 and nrc genes were down-regulated by 2.7 and 1.6-fold respectively. Expression of the prtA, lytB, and srtA genes was down-regulated by 1.9, 1.6, and 1.5-fold respectively.

A large number of genes involved in transcription and DNA binding were down-regulated in pyrimidinedione-grown biofilms. Expression of 23 transcription and DNA binding genes was down-regulated, while five genes were up-regulated. Important down-regulated genes include, ccpA, rpoC, comX2, bplS, spx, and cps2A. The ccpA gene encodes catabolite control protein A, which is a negative repressor protein with a regulatory role in carbohydrate metabolism. The comX2gene encodes a sigma factor that functions as a competence-specific global transcription modulator involved in bacterial competence.

Other down-regulated genes encoded cell membrane proteins, as well as proteins involved in amino acid synthesis, catalytic activity, cell wall organization and biogenesis, homeostasis, response to stress, and thiamine and riboflavin biosynthesis.
Table 2. Genes up-regulated in pneumococcal biofilms grown with pyrimidinedione.

| Gene locus/name | Protein | Molecule function | Biological process | Mean fold change in expression (p-value) |
|-----------------|---------|-------------------|-------------------|----------------------------------------|
| **Purine nucleotide biosynthetic process** | | | | |
| SPD_0051 (purC) | phosphoribosylaminimidazole-succinocarboxamide | ATP binding/phosphoribosylaminimidazole-succinocarboxamide synthase activity | 'de novo' IMP biosynthetic process | 2.3 (0.03) |
| **Carbohydrate metabolism** | | | | |
| SPD_0940 | UDP-N-acetyl-D-mannosaminuronic acid | NAD binding | polysaccharide biosynthetic process | 4.8 (0.01) |
| SPD_0236 (talc) | transaldolase, putative | sedoheptulose-7-phosphate:D-glyceraldehyde-3-phosphate glycerotransferase activity | pentose-phosphate shunt | 1.4 (0.01) |
| SPD_1046 (lacG-2) | 6-phospho-beta-galactosidase | 6-phospho-beta-galactosidase activity | lactose catabolic process via tagatose-6-phosphate | 5.3 (0.01) |
| SPD_1053 (lacA) | galactose-6-phosphate isomerase, LacA subunit | galactose-6-phosphate isomerase activity | galactose catabolic process | 1.4 (0.04) |
| SPD_1050 (lacD) | tagatose 1,6-diphosphate aldolase | tagatose-bisphosphate aldolase activity | lactose catabolic process via tagatose-6-phosphate | 1.4 (0.05) |
| SPD_1051 (lacC) | tagatose-6-phosphate kinase | tagatose-6-phosphate kinase activity | lactose catabolic process via tagatose-6-phosphate | 1.4 (0.05) |
| SPD_1613 (galT-1) | UDP-glucose:hexose-1-phosphate uridylyltransferase | UDP-glucose:hexose-1-phosphate uridylyltransferase activity | galactose metabolic process | 3.5 (0.03) |
| SPD_1612 (galE-2) | UDP-glucose 4-epimerase | coenzyme binding | galactose metabolic process | 1.4 (0.01) |
| SPD_1052 (lacB) | galactose-6-phosphate isomerase, LacB subunit | galactose-6-phosphate isomerase activity | galactose catabolic process | 1.4 (0.01) |
| **Transport** | | | | |
| SPD_0234 | PTS system, IIC component | protein-(N(Pi))-phosphohistidine-sugar phosphotransferase activity | phosphoenolpyruvate-dependent sugar phosphotransferase system | 1.4 (0.04) |
| SPD_1048 (lacF-2) | PTS system, lactose-specific IIA component | transferase activity | phosphoenolpyruvate-dependent sugar phosphotransferase system | 2.6 (0.01) |
| SPD_1047 (lacE-2) | PTS system, lactose-specific IIBC components | protein-(N(Pi))-phosphohistidine-lactose phosphotransferase system transporter activity | phosphoenolpyruvate-dependent sugar phosphotransferase system | 3.9 (0.03) |
| clgD (SPD_1860) | competence protein ClgD | Competence-related DNA transformation transporter (DNA-T) core components | Competence-related DNA transformation transporter (DNA-T) core components | 1.7 (0.03) |
| potD (SPD_1218) | spermidine/putrescine ABC transporter, | polyamine binding | polyamine transport | 1.4 (0.04) |
| **Response stress** | | | | |
| SPD_0286 | glutathione peroxidase | glutathione peroxidase activity | response to oxidative stress | 1.3 (0.04) |
| SPD_1287 (trxB) | thioredoxin-disulfide reductase | flavin adenine dinucleotide binding | removal of superoxide radicals | 1.5 (0.05) |
| **Transcription and DNA binding** | | | | |
| SPD_0280 | transcriptional regulator, putative | protein-(N(Pi))-phosphohistidine-sugar phosphotransferase activity | regulation of transcription, DNA-templated | 1.4 (0.05) |

(Continued)
### Table 2. (Continued)

| Gene locus/ name | Protein | Molecule function | Biological process | Mean fold change in expression (p-value) |
|------------------|---------|-------------------|--------------------|-----------------------------------------|
| **DNA-binding response regulator** | DNA-binding response regulator | DNA binding/sequence-specific DNA binding transcription factor activity | transcription, DNA-templated/phosphorelay signal transduction system | 1.5 (0.03) |
| **transcriptional regulator, putative** | transcriptional regulator, putative | sequence-specific DNA binding | DNA binding transcription factor activity | 3.5 (0.05) |
| **DNA-binding response regulator** | DNA-binding response regulator | sequence-specific DNA binding transcription factor activity | transcription, DNA-templated | 1.4 (0.05) |
| **transcription antiterminator LacT** | transcription antiterminator LacT | RNA binding | regulation of transcription, DNA-templated | 3.4 (0.01) |

**Nucleic acid phosphodiester bond hydrolysis**

| Gene locus/ name | Protein | Molecule function | Biological process | Mean fold change in expression (p-value) |
|------------------|---------|-------------------|--------------------|-----------------------------------------|
| SPD_0662 | endonuclease/exonuclease/phosphatase family | endonuclease activity | Not available | 1.5 (0.01) |
| **Translation** | | | | |
| SPD_0494 (valS) | valyl-tRNA synthetase | aminoacyl-tRNA editing activity | valyl-tRNA aminoacylation | 1.7 (0.05) |
| SPD_0757 (rpsA) | ribosomal protein S1 | RNA binding | translation | 1.4 (0.06) |
| SPD_0777 (thl) | thiamine biosynthesis/tRNA modification protein | tRNA adenylyltransferase activity | thiamine biosynthetic process | 1.4 (0.02) |

**Hydrolase activity**

| Gene locus/ name | Protein | Molecule function | Biological process | Mean fold change in expression (p-value) |
|------------------|---------|-------------------|--------------------|-----------------------------------------|
| SPD_1061 | serine/threonine protein phosphatase | hydrolase activity | | 1.4 (0.04) |
| SPD_1105 (Rnc) | ribonuclease III | ribonuclease III activity/rRNA binding/Endonuclease, Hydrolase, Nuclease | mRNA processing, rRNA processing, tRNA processing | 1.4 (0.01) |
| SPD_0266 | Cof family protein | hydrolase activity | Not available | 1.4 (0.02) |
| SPD_1180 | CAAAX amino terminal protease family protein | peptidase activity | | 3.5 (0.04) |

**One carbon metabolic process**

| Gene locus/ name | Protein | Molecule function | Biological process | Mean fold change in expression (p-value) |
|------------------|---------|-------------------|--------------------|-----------------------------------------|
| SPD_1087 (Fhs) | formate—tetrahydrofolate ligase | formate-tetrahydrofolate ligase activity | folic acid-containing compound biosynthetic process | 1.5 (0.03) |
| **Membrane protein** | | | | |
| SPD_1213 | membrane protein, putative | | | 1.7 (0.05) |
| **Signal transduction system** | | | | |
| SPD_1799 | sensor histidine kinase, putative | | phosphorelay sensor kinase activity | 1.4 (0.04) |

**Nucleobase-containing compound metabolic process**

| Gene locus/ name | Protein | Molecule function | Biological process | Mean fold change in expression (p-value) |
|------------------|---------|-------------------|--------------------|-----------------------------------------|
| SPD_0214 (Adk) | adenylate kinase | adenylate kinase activity | AMP salvage | 2.7 (0.05) |

**Hypothetical proteins**

| Gene locus/ name | Protein | Molecule function | Biological process | Mean fold change in expression (p-value) |
|------------------|---------|-------------------|--------------------|-----------------------------------------|
| SPD_1945 | membrane protein, putative | | | 3.0 (0.02) |
| SPD_0056 | vanZ protein, putative | | | 2.9 (0.04) |
| SPD_0935 | Tn5252, Orf 9 protein | | | 3.0 (0.05) |
| SPD_0023 | conserved hypothetical protein | | | 2.2 (0.05) |
| SPD_0094 | conserved hypothetical protein | | | 1.4 (0.02) |
| SPD_0668 | conserved hypothetical protein | | | 2.2 (0.05) |

(Continued)
Quantification of gene expression by real-time RT-PCR

Thirteen differentially expressed genes from our microarray analysis were confirmed by real-time RT-PCR, and their differential expression levels were in agreement with the microarray data (Table 4).

Pyrimidinedione does not exhibit eukaryotic cell toxicity

The CCK8 cell viability experiment revealed no significant difference in mean absorbance of HMEECs treated with 1, 5, or 10 μM pyrimidinedione with respect to untreated or DMSO-controls ($p > 0.45$). The absorbance of 2% triton X-100 treated HMEECs was significantly ($p < 0.002$) lower than control- or pyrimidinedione-treated cells, indicating no acute cellular cytotoxicity at the tested concentrations (Fig 12). Thus, pyrimidinedione showed no evidence of acute toxicity to human HMEECs at a concentration of 10 μM, which was 10-fold greater than the established EC₅₀.

Discussion

*S. pneumoniae* are known to cause various biofilm-related infections in human. The physiology, metabolism, and gene expression profile of biofilm bacteria are different than planktonic bacteria (18). In *S. pneumoniae* biofilms, the quorum sensing (QS) signal generated by competence stimulating peptide (CSP) plays an important role in coordinating the spatial distribution of cells and the aggregation of exopolysaccharides [34,35]. Autoinducer-2 (AI-2) is the only QS molecule in pneumococci synthesized through activated methyl cycle (AMC), where Dam enzyme catalyze the transfer of a methyl group from SAM to macromolecules and adenine within DNA duplex [36,37,38]. Therefore, we hypothesized that interfering in Dam activity could have adverse effect on *S. pneumoniae* biofilms growth. Several studies reported that DNA adenine methylation regulates the expression of various virulence-related genes in
Table 3. Gene down-regulated in pneumococcal biofilms grown with pyrimidinedione.

| Gene locus/name | Protein | Molecular function | Biological function | Mean fold gene expression (p-value) |
|-----------------|---------|--------------------|---------------------|-------------------------------------|
| **DNA replication** | | | | |
| SPD_0002 (dnaN) | DNA polymerase III, beta subunit | 3'-5' exonuclease activity/DNA-directed DNA polymerase activity | DNA replication | -1.5 (0.009) |
| SPD_0760 (dnaX) | DNA polymerase III, gamma and tau subunits | ATP binding/DNA-directed DNA polymerase activity | DNA replication | -2.6 (0.01) |
| SPD_2054 (recF) | recF protein | ATP binding | DNA replication/Repair | -1.4 (0.002) |
| **Integral component of membrane** | | | | |
| SPD_0040 | membrane protein, putative | integral component of membrane | | -1.5 (0.004) |
| SPD_0523 (vex3) | ABC transporter, transmembrane protein Vexp3 | | Integral component of membrane | -1.5 (0.003) |
| **Transcription and DNA binding** | | | | |
| SPD_0064 | transcriptional regulator, GntR family protein | DNA binding/sequence-specific DNA binding transcription factor activity | transcription, DNA-templated | -1.5 (0.01) |
| SPD_0379 | transcriptional regulator, MarR family protein | DNA binding | Transcription | -2.0 (0.03) |
| SPD_0447 | transcriptional regulator, MerR family protein | DNA binding | regulation of transcription, DNA-templated | -1.6 (0.03) |
| SPD_0458 (hrcA) | heat-inducible transcription represer HrcA | DNA binding | transcription, DNA-templated | -1.4 (0.04) |
| SPD_0479 (nusA) | transcription termination factor NusA | RNA binding/sequence-specific DNA binding transcription factor activity | Regulation of DNA-templated transcription, termination | -1.6 (0.05) |
| SPD_1134 (pyrR) | pyrimidine operon regulatory protein/uracil | RNA binding/uracil phosphoribosyltransferase activity | DNA-templated transcription, termination | -1.4 (0.001) |
| SPD_1523 | transcriptional regulator, NrdR family protein | DNA binding | negative regulation of transcription, DNA-templated | -1.5 (0.02) |
| SPD_1547 | DNA-directed RNA polymerase omega chain | DNA-directed RNA polymerase activity | transcription, DNA-templated | -1.6 (0.01) |
| SPD_0081 | DNA-binding response regulator | DNA binding | transcription, DNA-templated | -1.5 (0.007) |
| SPD_1758 (rpoC) | DNA-directed RNA polymerase, beta' subunit | DNA-directed RNA polymerase activity | transcription, DNA-templated | -1.5 (0.01) |
| SPD_1797 (ccpA) | catabolite control protein A | sequence-specific DNA binding transcription factor activity | transcription, DNA-templated | -1.4 (0.01) |
| SPD_1819 (nusG) | transcription termination/antitermination factor | DNA-templated transcription, elongation | | -1.7 (0.04) |
| SPD_1818 (comX2) | transcriptional regulator ComX2 | sequence-specific DNA binding transcription factor activity | DNA-templated transcription, initiation | -1.4 (0.002) |
| SPD_0467 (blpS) | BlpS protein | DNA binding | | -1.5 (0.04) |
| SPD_1594 | transcriptional regulator | sequence-specific DNA binding | DNA binding | -1.9 (0.001) |
| SPD_1236 (spx) | regulatory protein Spx | | | -1.4 (0.05) |
| SPD_0691 | transcriptional regulator, PadR family protein | | | -1.8 (0.004) |
| SPD_0908 | Sua5/YciO/YrdC/YwlC family protein | double-stranded RNA binding | | -1.6 (0.01) |
| SPD_1014 | IS630-Spn1, transposase Orf1 | DNA binding | | -1.6 (0.01) |
| SPD_1594 | transcriptional regulator | sequence-specific DNA binding | DNA binding | -1.9 (0.001) |
| SPD_0716 | IS630-Spn1, transposase Orf1 | DNA binding | | -1.6 (0.05) |
| SPD_1708 | IS1167, transposase | DNA binding | transposition, DNA-mediated | -1.4 (0.01) |

(Continued)
| Gene locus/ name | Protein | Molecular function | Biological function | Mean fold gene expression (p-value) |
|-----------------|---------|---------------------|---------------------|-----------------------------------|
| SPD_1521 (dnai) | primosomal protein DnaI | ATP binding | DNA replication | -1.4 (0.03) |
| SPD_0315 (cps2A) | integral membrane regulatory protein Cps2A | DNA replication | DNA replication | -2.0 (0.03) |
| **Transport** | | | | |
| SPD_0069 | PTS system, IIA component | cation transport | phosphoenolpyruvate-dependent sugar phosphotransferase system | -2.6 (0.01) |
| SPD_0076 | potassium uptake protein, Trk family protein | cation transport | phosphoenolpyruvate-dependent sugar phosphotransferase system | -1.5 (0.01) |
| SPD_0224 | iron(III) ABC transporter, permease protein | transport | transport | -1.6 (0.01) |
| SPD_0424 | PTS system, cellubiose-specific IIC component | transport | phosphoenolpyruvate-dependent sugar phosphotransferase system | -1.5 (0.03) |
| SPD_1141 (uraA) | uracil-xanthine permease | transporter activity | transport membrane transport | -1.4 (0.05) |
| SPD_1425 | transporter, major facilitator family protein | transporter activity | transport membrane transport | -4.2 (0.03) |
| SPD_1425 | transporter, major facilitator family protein | transporter activity | transport membrane transport | -4.2 (0.03) |
| SPD_1409 | sugar ABC transporter, ATP-binding protein | hydrolase activity, acting on acid anhydrides, catalyzing transport membrane movement of substances | -1.4 (0.02) |
| SPD_1820 (secE) | preprotein translocase, SecE subunit | P-P-bond-hydrolysis-driven protein transport membrane transport activity | protein secretion | -1.7 (0.006) |
| SPD_1847 | PTS system, membrane component, putative | transferase activity | phosphoenolpyruvate-dependent sugar phosphotransferase system | -1.6 (0.02) |
| SPD_1832 | PTS system, IIB component | protein-N(Pi)-phosphohistidine-sugar phosphotransferase activity | phosphoenolpyruvate-dependent sugar phosphotransferase system | -1.4 (0.05) |
| SPD_1831 | PTS system, IIC component | protein-N(Pi)-phosphohistidine-sugar phosphotransferase activity | phosphoenolpyruvate-dependent sugar phosphotransferase system | -1.7 (0.04) |
| SPD_1833 | PTS system, IIA component | transferase activity | phosphoenolpyruvate-dependent sugar phosphotransferase system | -1.6 (0.01) |
| SPD_1934 (matX) | maltose/maltodextrin ABC transporter | maltose transport membrane transport activity | -1.4 (0.01) |
| SPD_2026 | ABC transporter, permease protein | transport | -1.6 (0.01) |
| SPD_0400 | Glycosyl transferase family protein 8, putative | transferase activity, transferring glycosyl groups | -1.5 (0.05) |
| SPD_1677 (rafE) | sugar ABC transporter, sugar-binding protein | transporter activity | -1.9 (0.05) |
| SPD_1755 | ABC transporter, ATP-binding protein | ATPase activity | -1.9 (0.02) |

(Continued)
| Gene locus/name | Protein | Molecular function | Biological function | Mean fold gene expression (p-value) |
|----------------|---------|--------------------|---------------------|-----------------------------------|
| SPD_1738 (dinF) | MATE efflux family protein DinF | drug transmembrane transporter activity | -2.2 (0.05) |
| SPD_1528 | ABC transporter, ATP-binding protein | ATPase activity | -1.7 (0.002) |
| SPD_1438 | cadmium resistance transporter, putative | | -1.4 (0.01) |
| SPD_1431 | glycosyl transferase, group 2 family protein | transferase activity, transferring glycosyl groups | -1.4 (0.04) |
| SPD_1383 | cation-transporting ATPase, E1-E2 family | | -1.5 (0.03) |
| SPD_1176 | ABC transporter, ATP-binding protein | ATPase activity/ATP binding | -1.9 (0.02) |
| SPD_0960 (cpoA) | glycosyl transferase CpoA | transferase activity, transferring glycosyl groups | biosynthetic process -2.0 (0.01) |
| SPD_0189 | acetyltransferase, GNAT family protein | N-acetyltransferase activity | -2.3 (0.03) |
| **Phosphate ABC transporter** | | | |
| SPD_1912 (pstA) | phosphate ABC transporter, permease protein | inorganic phosphate transmembrane transporter activity | phosphate ion transmembrane transport -1.7 (0.01) |
| SPD_1910 (pstS) | phosphate ABC transporter, phosphate-binding | ABC transporters | Signal transduction -1.8 (0.05) |
| SPD_1913 (pstB) | phosphate ABC transporter, ATP-binding protein | phosphate ion transmembrane-transporting ATPase activity | -1.9 (0.008) |
| SPD_1914 (phoU) | phosphate transport system regulatory protein | phosphate ion transport | -2.2 (0.01) |
| SPD_1911 (pstC) | phosphate ABC transporter, permease protein | inorganic phosphate transmembrane transporter activity | phosphate ion transport -1.6 (0.01) |
| **Signal transduction** | | | |
| SPD_0082 | sensor histidine kinase | ATP binding/phosphorelay sensor kinase activity | -1.4 (0.001) |
| SPD_0701 (ciaR) | DNA-binding response regulator CiaR | | -1.4 (0.002) |
| SPD_0702 (ciaH) | sensor histidine kinase CiaH | ATP binding/phosphorelay sensor kinase activity | -1.5 (0.003) |
| SPD_2065 (comC1) | competence-stimulating peptide type 1 | Two-component system | -1.5 (0.005) |
| SPD_1040 (ptsH) | phosphocarrier protein HPc | protein serine/threonine kinase activity | phosphoenolpyruvate-dependent sugar phosphotransferase system -1.6 (0.005) |
| **Membrane protein** | | | |
| SPD_0080 | cell wall surface anchor family protein | Cell wall component | -1.7 (0.005) |
| SPD_0162 | membrane protein, putative | | -2.5 (0.05) |
| SPD_0282 | membrane protein, putative | | -1.8 (0.05) |
| SPD_1237 | membrane protein, putative | | -4.6 (0.009) |
| SPD_1265 | membrane protein, putative | | -1.5 (0.008) |
| SPD_1422 | membrane protein, putative | Membrane protein | -1.5 (0.006) |
| SPD_1426 | membrane protein, putative | | -1.9 (0.04) |
| SPD_1175 | membrane protein, putative | | -1.4 (0.02) |
| SPD_1717 | membrane protein, putative | | -2.6 (0.01) |

(Continued)
Table 3. (Continued)

| Gene locus/ name | Protein | Molecular function | Biological function | Mean fold gene expression (p-value) |
|------------------|---------|---------------------|---------------------|-------------------------------------|
| SPD_1589         | lipoprotein, putative | -2.3 (0.01) |
| SPD_1527         | membrane protein, putative | -2.1 (0.04) |
| SPD_1965 (pcpA)  | choline binding protein PcpA | -1.7 (0.003) |
| SPD_0129 (gidA)  | tRNA uridine 5-carboxymethylaminomethyl | flavin adenine dinucleotide binding | tRNA wobble uridine modification | -2.1 (0.05) |
| SPD_0258 (pepS)  | aminopeptidase PepS | aminopeptidase activity | -1.8 (0.01) |
| SPD_0308 (clpL)  | ATP-dependent Clp protease, ATP-binding subunit | ATP binding/peptidase activity | -1.5 (0.006) |
| SPD_0558 (ptA)   | cell wall-associated serine protease PrtA | serine-type endopeptidase activity | -1.9 (0.04) |
| SPD_0577 (zmpB)  | zinc metalloprotease ZmpB | metalloendopeptidase activity/zinc ion binding | -1.4 (0.03) |
| SPD_0167 (ribB)  | 3,4-dihydroxy-2-butanone 4-phosphate synthase activity/GTP binding | riboflavin biosynthetic process | -2.2 (0.007) |
| SPD_0168 (ribE)  | riboflavin synthase, alpha subunit | oxidoreductase activity/riboflavin synthase activity | riboflavin biosynthetic process | -1.7 (0.006) |
| SPD_0192 (rpsJ)  | ribosomal protein S10 | structural constituent of ribosome/rRNA binding | translation | -1.5 (0.01) |
| SPD_0194 (rplD)  | ribosomal protein L4 | rRNA binding | translation | -1.4 (0.003) |
| SPD_0197 (rpsS)  | ribosomal protein S19 | rRNA binding/structural constituent of ribosome | translation | -1.4 (0.01) |
| SPD_0198 (rplV)  | ribosomal protein L22 | rRNA binding/structural constituent of ribosome | translation | -1.7 (0.02) |
| SPD_0199 (rpsC)  | ribosomal protein S3 | rRNA binding | translation | -1.4 (0.006) |
| SPD_0201 (rpmC)  | ribosomal protein L29 | structural constituent of ribosome | translation | -1.5 (0.01) |
| SPD_0202 (rpsQ)  | ribosomal protein S17 | rRNA binding/structural constituent of ribosome | translation | -1.9 (0.04) |
| SPD_0204 (rplX)  | ribosomal protein L24 | rRNA binding/structural constituent of ribosome | translation | -1.7 (0.03) |
| SPD_0083 (rpsD)  | ribosomal protein S4 | rRNA binding/structural constituent of ribosome | translation | -1.4 (0.005) |
| SPD_0835 (frr)   | ribosome recycling factor | translational termination | -1.7 (0.03) |
| SPD_1148 (rpsS)  | ribosomal protein L19 | structural constituent of ribosome | translation | -1.6 (0.002) |
| SPD_0906 (prfA)  | peptide chain release factor 1 | translation release factor activity, codon specific | -2.9 (0.03) |
| SPD_1245 (rpsU)  | ribosomal protein S21 | -1.6 (0.05) |
| SPD_1370 (rpsF)  | ribosomal protein S6 | -1.4 (0.03) |

(Continued)
| Gene locus/ name | Protein | Molecular function | Biological function | Mean fold gene expression (p-value) |
|-----------------|---------|---------------------|---------------------|-----------------------------------|
| SPD_0481        | ribosomal protein L7A family protein | Ribonucleoprotein, Ribosomal protein | fatty acid biosynthetic process | -1.7 (0.01) |
| SPD_2033        | ribosomal subunit interface protein | | | -2.2 (0.006) |

**Fatty acid biosynthetic process**

| Gene locus/ name | Protein | Molecular function | Biological function | Mean fold gene expression (p-value) |
|-----------------|---------|---------------------|---------------------|-----------------------------------|
| SPD_0380 (fabH) | 3-oxoacyl-[acyl-carrier-protein] synthase III | 3-oxoacyl-[acyl-carrier-protein] synthase activity/beta-ketoacyl-acyl-carrier-protein synthase III activity | fatty acid biosynthetic process | -1.9 (0.009) |
| SPD_0381 (accP) | acyl carrier protein | ACP phosphopantetheine attachment site binding involved in fatty acid biosynthetic process | | -1.9 (0.007) |
| SPD_0382 (fabK) | trans-2-enoyl-ACP reductase II | nitrate monooxygenase activity | | -1.8 (0.01) |
| SPD_0383 (fabD) | malonyl CoA-acyl carrier protein transacylase | [acyl-carrier-protein] S-malonyltransferase activity | | -2.2 (0.008) |
| SPD_0384 (fabG) | 3-oxoacyl-[acyl-carrier-protein] reductase | | | -1.4 (0.05) |
| SPD_0387 (fabZ) | beta-hydroxyacyl-(acyl-carrier-protein) reductase | 3-hydroxyoctanoyl-[acyl-carrier-protein] dehydratase activity | fatty acid biosynthetic process | -1.6 (0.03) |
| SPD_0385 (fabF) | 3-oxoacyl-[acyl-carrier-protein] synthase II | beta-ketoacyl-acyl-carrier-protein synthase II activity | fatty acid biosynthetic process | -1.9 (0.008) |
| SPD_0386 (accB) | acetyl-CoA carboxylase, biotin carboxyl carrier | acetyl-CoA carboxylase activity | fatty acid biosynthetic process | -1.5 (0.001) |
| SPD_0387 (accC) | acetyl-CoA carboxylase, biotin carboxylase | acetyl-CoA carboxylase activity/biotin carboxylase activity | | -1.9 (0.05) |
| SPD_0388 (accD) | acetyl-CoA carboxylase, carboxyl transferase, | acetyl-CoA carboxylase activity/transferase activity | fatty acid biosynthetic process | -1.7 (0.05) |
| SPD_0390 (accA) | acetyl-CoA carboxylase, carboxyl transferase, | acetyl-CoA carboxylase activity/ATP binding | fatty acid biosynthetic process | -1.9 (0.03) |
| SPD_0856 (dgkA) | diacylglycerol kinase | diacylglycerol kinase activity | phospholipid biosynthetic process | -1.5 (0.05) |
| SPD_0347 (mvdD) | diphosphomevalonate decarboxylase | ATP binding/kinase activity | isopentenyl diphosphate biosynthetic process, mevalonate pathway | -1.7 (0.03) |

**Protein folding**

| Gene locus/ name | Protein | Molecular function | Biological function | Mean fold gene expression (p-value) |
|-----------------|---------|---------------------|---------------------|-----------------------------------|
| SPD_0459 (grpE) | heat shock protein GrpE | adenyl-nucleotide exchange factor activity | protein folding | -1.9 (0.02) |
| SPD_0460 (dnaK) | chaperone protein DnaK | ATP binding | protein folding | -2.1 (0.01) |
| SPD_1709 (groL) | chaperonin GroEL | ATP binding | protein refolding | -1.4 (0.03) |
| SPD_0461 (dnaJ) | chaperone protein DnaJ | ATP binding/zinc ion binding | DNA replication | -1.5 (0.05) |

**de novo' pyrimidine nucleobase metabolic process**

| Gene locus/ name | Protein | Molecular function | Biological function | Mean fold gene expression (p-value) |
|-----------------|---------|---------------------|---------------------|-----------------------------------|
| SPD_0608 (pyrF) | orotidine 5'-phosphate decarboxylase | orotidine-5'-phosphate decarboxylase activity | de novo' pyrimidine nucleobase biosynthetic process | -1.4 (0.05) |
| SPD_1133 (pyrB) | aspartate carbamoyltransferase | amino acid binding/aspartate carbamoyltransferase activity | de novo' pyrimidine nucleobase biosynthetic process | -1.4 (0.03) |
| SPD_0609 (pyrE) | orotate phosphoribosyltransferase | magnesium ion binding/orotate phosphoribosyltransferase activity | de novo' UMP biosynthetic process | -1.4 (0.01) |

(Continued)
### Table 3. (Continued)

| Gene locus/ name | Protein | Molecular function | Biological function | Mean fold gene expression (p-value) |
|------------------|---------|--------------------|---------------------|------------------------------------|
| SPD_1548 (gmk)   | guanylate kinase | ATP binding | purine nucleotide metabolic process | -1.5 (0.05) |
| SPD_0834 (pyR)   | uridylate kinase | ATP binding/UMP kinase activity | de novo CTP biosynthetic process | -1.4 (0.008) |

### Thiamine biosynthetic process

| Gene locus/ name | Protein | Molecular function | Biological function | Mean fold gene expression (p-value) |
|------------------|---------|--------------------|---------------------|------------------------------------|
| SPD_0624 (thiE-1) | thiamine-phosphate pyrophosphorylase | magnesium ion binding/thiamine-phosphate diphosphorylase activity | thiamine biosynthetic process | -1.5 (0.007) |
| SPD_0628 (tenA)  | transcriptional activator TenA, TENA/THI-4 | thiaminase activity | thiamine metabolic process | -1.4 (0.01) |
| SPD_1779         | thiamine pyrophosphokinase | thiamine binding | thiamine metabolic process | -1.5 (0.03) |

### Cell division

| Gene locus/ name | Protein | Molecular function | Biological function | Mean fold gene expression (p-value) |
|------------------|---------|--------------------|---------------------|------------------------------------|
| SPD_0659 (ftsE)  | cell division ATP-binding protein FtsE | ATPase activity/ATP binding | cell division | -1.7 (0.02) |
| SPD_1477 (yImF)  | YlmF protein | barrier septum assembly | barrier septum assembly | -1.5 (0.003) |
| SPD_1478 (yImE)  | YlmE protein | GTPase activity | barrier septum assembly | -1.4 (0.03) |
| SPD_1479 (ftsZ)  | cell division protein FtsZ | GTPase activity | barrier septum assembly | -1.4 (0.05) |

### Carbohydrate metabolism

| Gene locus/ name | Protein | Molecular function | Biological function | Mean fold gene expression (p-value) |
|------------------|---------|--------------------|---------------------|------------------------------------|
| SPD_0723 (rpiA)  | ribose 5-phosphate isomerase A | ribose-5-phosphate isomerase activity | pentose-phosphate shunt, non-oxidative branch | -1.5 (0.03) |
| SPD_0790 (pyk)   | pyruvate kinase | magnesium ion binding/potassium ion binding | glycolytic process | -1.4 (0.02) |
| SPD_1012 (enol)  | phosphopyruvate hydratase | magnesium ion binding/phosphopyruvate hydratase activity | glycolytic process | -1.4 (0.01) |
| SPD_0420 (pflB)  | formate acetyltransferase | formate C-acetyltransferase activity | carbohydrate metabolic process | -1.6 (0.03) |
| SPD_1823 (gap)   | glyceraldehyde-3-phosphate dehydrogenase, type | oxidoreductase activity, acting on the aldehyde or o xo group of donors, NAD or NADP as acceptor | glucose metabolic process | -1.8 (0.04) |
| SPD_1582         | sucrose-6-phosphate hydrolase, putative | sucrose alpha-glucosidase activity | carbohydrate metabolic process | -1.6 (0.006) |
| SPD_0143         | UDP-glucose 6-dehydrogenase, putative | NAD binding/UDP-glucose 6-dehydrogenase activity | polysaccharide biosynthetic process | -2.1 (0.02) |
| SPD_0870         | phosphoglycerate mutase family protein | | | -2.5 (0.009) |

### Hydrolases

| Gene locus/ name | Protein | Molecular function | Biological function | Mean fold gene expression (p-value) |
|------------------|---------|--------------------|---------------------|------------------------------------|
| SPD_1076 (srtA)  | sortase | | | -1.5 (0.005) |

### Cellular amino acid biosynthesis

| Gene locus/ name | Protein | Molecular function | Biological function | Mean fold gene expression (p-value) |
|------------------|---------|--------------------|---------------------|------------------------------------|
| SPD_1209 (aroB)  | 3-dehydroquinate synthase | 3-dehydroquinate synthase activity | aromatic amino acid family biosynthetic process | -1.6 (0.008) |
| SPD_1372         | glyoxalase family protein | | | -1.4 (0.05) |
| SPD_0764 (sufS)  | cysteine desulfurases, SufS subfamily protein | cysteine desulfurase activity/pyridoxal phosphate binding | cysteine metabolic process | -1.4 (0.009) |
| SPD_1899         | glutamine amidotransferase, class 1 | hydrolase activity | glutamine metabolic process | -1.5 (0.02) |

### Catalytic activity

| Gene locus/ name | Protein | Molecular function | Biological function | Mean fold gene expression (p-value) |
|------------------|---------|--------------------|---------------------|------------------------------------|
| SPD_1411         | isochorismatase family protein | catalytic activity | | -1.4 (0.04) |

(Continued)
| Gene locus/ name | Protein | Molecular function | Biological function | Mean fold gene expression (p-value) |
|-----------------|---------|--------------------|---------------------|-----------------------------------|
| SPD_1555 isochorismatase family protein | catalytic activity | cell redox homeostasis/glycerol ether metabolic process | -1.4 (0.01) |
| SPD_0852 dihydroidoate dehydrogenase, catalytic subunit | catalytic activity | cell redox homeostasis | -1.4 (0.02) |
| **Homeostasis process** | | | | |
| SPD_1714 thioredoxin family protein | protein disulfide oxidoreductase activity | cell redox homeostasis | -1.4 (0.05) |
| SPD_1464 thiol peroxidase | thioredoxin peroxidase activity | cell redox homeostasis | -2.2 (0.004) |
| SPD_1041 glutaredoxin-like protein NrdH | electron carrier activity/protein disulfide oxidoreductase activity | cell redox homeostasis | -1.7 (0.03) |
| SPD_1028 TPP-dependent acetoin dehydrogenase | oxidoreductase activity, acting on the aldehyde or oxo group of donors, disulfide as acceptor | | -1.4 (0.02) |
| SPD_0190 anaerobic ribonucleoside-triphosphate reductase | [formate-C-acetyltransferase]-activating enzyme activity/4 iron, 4 sulfur cluster binding | | -2.7 (0.02) |
| **Pathogenesis/cytolysis** | | | | |
| SPD_1726 pneumolysin | cholesterol binding | hemolysis of cells in other organism/pathogenesis | -1.5 (0.005) |
| SPD_1295 hemolysin | | | -2.7 (0.03) |
| SPD_0729 hemolysin-related protein | cholesterol binding | pathogenesis | -1.6 (0.005) |
| **Response to stress** | | | | |
| SPD_1590 general stress protein 24, putative | | | -1.6 (0.001) |
| SPD_0667 superoxide dismutase, manganese-dependent | metal ion binding/superoxide dismutase activity | | -1.4 (0.003) |
| SPD_1135 endonuclease III | 4 iron, 4 sulfur cluster binding/DNA-(apurinic or apyrimidinic site) lyase activity | base-excision repair | -2.1 (0.004) |
| **Cell wall organization and biogenesis** | | | | |
| SPD_0853 endo-beta-N-acetylglicosaminidase precursor | amidase activity/mannosyl-glycoprotein endo-beta-N-acetylglicosaminidase activity | | -1.6 (0.05) |
| **Conserved hypothetical protein** | | | | |
| SPD_0030 conserved hypothetical protein | | | -1.5 (0.001) |
| SPD_0145 conserved hypothetical protein | | | -1.4 (0.001) |
| SPD_0164 conserved hypothetical protein | | | -1.8 (0.01) |
| SPD_0181 conserved hypothetical protein | | | -1.4 (0.02) |
| SPD_0182 conserved hypothetical protein | | | -1.8 (0.009) |
| SPD_0256 conserved hypothetical protein | | | -1.6 (0.01) |
| SPD_0302 conserved hypothetical protein | | | -1.4 (0.002) |
| SPD_0339 conserved hypothetical protein | | | -1.5 (0.03) |
| SPD_0410 conserved hypothetical protein | | | -1.4 (0.05) |
| SPD_0425 conserved hypothetical protein | | | -1.9 (0.02) |
| SPD_0478 conserved hypothetical protein | | | -1.8 (0.05) |
| SPD_0488 conserved hypothetical protein | | | -2.2 (0.001) |
| SPD_0489 conserved hypothetical protein | | | -1.6 (0.007) |
| SPD_0499 conserved hypothetical protein | | | -1.4 (0.002) |
| SPD_0594 conserved hypothetical protein | | | -1.8 (0.008) |
| SPD_0681 conserved hypothetical protein | | | -1.3 (0.04) |
| SPD_0714 conserved hypothetical protein | | | -1.5 (0.03) |

(Continued)
numerous pathogens [39,40,41]. Our previous study demonstrated that interfering with methylation activity, either using the hypo-methylating agent (5-azacytidine) or a SAM analogue (sinefungin), inhibited pneumococcal biofilm growth. In this study, we examined the effect of the small molecule Dam inhibitor, pyrimidinedione, on *S. pneumoniae* biofilm growth. We then evaluated global gene expression changes within biofilms grown in the presence of pyrimidinedione.

Planktonic cell growth of *S. pneumoniae* D39 was not inhibited in the presence of different pyrimidinedione concentrations. The CV-microtiter plate assay and cfu counts detected a significant decrease in biofilm formation in samples treated with pyrimidinedione, and this inhibitory effect was concentration-dependent in all serotypes tested. The normal growth of planktonic cells and decreased biofilm formation in presence of pyrimidinedione indicated that pyrimidinedione selectively inhibits pneumococcal biofilms. Similarly, the Dam mutant strains of *Yersinia enterocolitica* and *Haemophilus influenzae* showed reduced adhesion and host cell invasion capacity [42,43]. Pyrimidinedione was effective in inhibiting pneumococcal biofilm growth at both early and late stages [44]. Similar inhibitory effects of 5-aza-cytidine

| Gene locus/name | Protein                        | Molecular function | Biological function | Mean fold gene expression (p-value) |
|-----------------|--------------------------------|--------------------|---------------------|-------------------------------------|
| SPD_0791        | conserved hypothetical protein |                    |                     | -2.1 (0.01)                         |
| SPD_0911        | conserved hypothetical protein |                    |                     | -1.6 (0.05)                         |
| SPD_0929        | conserved hypothetical protein |                    |                     | -1.7 (0.04)                         |
| SPD_0959        | conserved hypothetical protein |                    |                     | -1.9 (0.02)                         |
| SPD_0962        | conserved hypothetical protein |                    |                     | -1.4 (0.008)                        |
| SPD_0990        | conserved hypothetical protein |                    |                     | -1.7 (0.02)                         |
| SPD_1003        | conserved hypothetical protein |                    |                     | -1.4 (0.03)                         |
| SPD_1159        | conserved hypothetical protein |                    |                     | -1.3 (0.05)                         |
| SPD_1171        | conserved hypothetical protein |                    |                     | -1.4 (0.007)                        |
| SPD_1242        | conserved hypothetical protein |                    |                     | -1.4 (0.04)                         |
| SPD_1294        | conserved hypothetical protein |                    |                     | -2.8 (0.05)                         |
| SPD_1344        | conserved hypothetical protein |                    |                     | -1.8 (0.03)                         |
| SPD_1380        | conserved hypothetical protein |                    |                     | -1.2 (0.007)                        |
| SPD_1400        | conserved hypothetical protein |                    |                     | -1.5 (0.02)                         |
| SPD_1558        | conserved hypothetical protein |                    |                     | -1.6 (0.01)                         |
| SPD_1566        | conserved hypothetical protein |                    |                     | -2.3 (0.01)                         |
| SPD_1588        | conserved hypothetical protein |                    |                     | -1.6 (0.01)                         |
| SPD_1595        | conserved hypothetical protein |                    |                     | -1.9 (0.004)                        |
| SPD_1662        | conserved hypothetical protein |                    |                     | -1.6 (0.01)                         |
| SPD_1716        | conserved hypothetical protein |                    |                     | -1.8 (0.008)                        |
| SPD_1718        | conserved hypothetical protein |                    |                     | -2.7 (0.002)                        |
| SPD_1725        | conserved hypothetical protein |                    |                     | -1.6 (0.004)                        |
| SPD_1728        | conserved hypothetical protein |                    |                     | -1.8 (0.008)                        |
| SPD_1727        | conserved hypothetical protein |                    |                     | -1.8 (0.005)                        |
| SPD_1729        | conserved hypothetical protein |                    |                     | -1.6 (0.002)                        |
| SPD_1858        | conserved hypothetical protein |                    |                     | -1.5 (0.007)                        |
| SPD_0855        | conserved hypothetical protein |                    |                     | -1.4 (0.05)                         |
| SPD_1836        | conserved hypothetical protein |                    |                     | -1.4 (0.05)                         |

doi:10.1371/journal.pone.0139238.t003
and sinefungin on *S. pneumoniae* biofilms as well as a small molecule adenosine mimic on *Salmonella enterica* biofilms were previously reported [27,28,45]. However, pyrimidinedione was not effective in dismantling biofilms nor was it cytotoxic to bacteria within biofilms. *S. aureus* and *S. epidermidis* are important pathogens implicated in a wide variety of biofilm-related infections, including infections present within medical devices. The inhibitory effects of pyrimidinedione on *S. aureus* (MSSA and MRSA) and *S. epidermidis* biofilms indicated broad-spectrum anti-biofilm activity against antibiotic-resistant bacteria.

To understand biofilm changes at the microscopic level, we examined biofilms grown with and without pyrimidinedione by confocal microscopy and SEM. In microscopic analysis, the control and pyrimidinedione–biofilms demonstrated a significantly different morphology. The control biofilms were well organized and compact with significant thickness, and the cells were interconnected with each other and to the base of the plate [46]. A remarkable feature of these control biofilms was the presence of EPS [47]. EPS was completely absent in biofilms grown
with pyrimidinedione. Due to lack of EPS, the cells were scattered, attached only to the bottom of the plate, and were unable to form an organized biofilm structure [48]. EPS is important for biofilm development; the absence of this structure indicated that bacteria were attached to the bottom of the plate. Therefore, it is possible that they could be easily washed away, decreasing biofilm biomass calculations and cfu counts [49].

In order to examine the changes in gene expression of pyrimidinedione-grown biofilms, we evaluated global gene expression by microarray analysis. The overall gene expression pattern demonstrated that more genes were down-regulated in pyrimidinedione-grown biofilms compared to control biofilms. The gene expression analysis of 13 differentially expressed genes identified by microarray was confirmed using real-time RT-PCR. A functional annotation

Fig 10. Schematic representation of central metabolic pathways in Streptococcus pneumoniae D39. In pneumococci, lactose and galactose are metabolized by the tagatose-6-phosphate pathway (light orange box) and the Leloir pathway (left; light green box). Tagatose-6-phosphate pathway genes include lacA, lacB, lacC, and lacD, and Leloir pathway genes include galM, galK, galT-1, and galE-2. Along with these the lacF2 gene (encodes the PTS system, lactose-specific IIA component) and lacE2 gene (encodes the PTS system, lactose-specific IIBC component) are required for galactose transport. The gap gene (encoding glyceraldehyde-3-phosphate dehydrogenase), eno gene (encoding phosphopyruvate hydratase), and pyk gene (encoding pyruvate kinase) are involved in glycolysis (central blue box). The lacA, lacB, lacC, lacD, galT-1, galE-2, gap, eno and pyk genes were down-regulated by more than 1.4 folds in this study. The relative fold-changes in gene expression are highlighted.

doi:10.1371/journal.pone.0139238.g010
demonstrated that 17 functional gene groups were exclusively down-regulated, and four clusters were exclusively up-regulated in pyrimidinedione-grown biofilms.

The down-regulation of genes involved in DNA replication, cell division, cell organization and biogenesis, response to stress, homeostasis, and protein folding indicated that cell division may be perturbed and that cells were stressed in the presence of pyrimidinedione. In support of this hypothesis, 13 genes encoding ribosomal proteins showed reduced transcription in pyrimidinedione-grown biofilms, indicating that the pneumococci had reduced its translational capacity [50]. Similarly, bacterial transcriptional, signaling, and transport capacity may also be obstructed by down-regulation of transcription, DNA binding, transport, and signaling protein-encoding genes in pyrimidinedione-grown biofilms.

Fatty acid biosynthesis is essential for bacterial membrane integrity and cellular physiology, and the fatty acid biosynthesis gene mutant strains were unable to survive [51]. Pneumococcal fatty acid biosynthesis genes are collectively known as type II fatty acid synthase, which are clustered at a single location. The down-regulation of fatty acid biosynthesis genes in

![Fig 11. Fatty acid biosynthesis gene locus in Streptococcus pneumoniae. (A) FAS involves 13 genes that are arranged in a single locus that initiate fatty acid synthesis and product elongation. The fatty acid synthesis genes include: acpP, encoding acyl carrier protein (ACP); accD, encoding acetyl coenzyme A (acetyl-CoA) carboxylase subunit beta; fabG, encoding 3-ketoacyl-ACP reductase; fabH, encoding 3-oxoacyl-ACP synthase III; fabK, encoding trans-2-enoyl-ACP reductase II; fabD, encoding ACP S-malonyltransferase; fabF, encoding 3-oxoacyl-ACP synthase II; fabZ, encoding (3R)-hydroxymyristoyl-ACP dehydratase; accA, encoding acetyl coenzyme A (acetyl-CoA) carboxylase subunit alpha; accB, encoding acetyl coenzyme A (acetyl-CoA) carboxylase subunit and accC, encoding acetyl coenzyme A (acetyl-CoA) carboxylase subunit. (B) The interconnection of fatty acid genes detected by STRING v9.1 on the basis of terms on the right. The fold-changes in gene expression are highlighted. doi:10.1371/journal.pone.0139238.g011]
A striking observation in our microarray and real-time RT-PCR gene expression results was the up-regulation of galactose metabolic pathway genes and down-regulation of glycolysis pathway genes. In pneumococci, lactose and galactose are metabolized by the tagatose-6-phosphate and Leloir pathways, respectively [52,53,54]. Our results demonstrated up-regulation of tagatose pathway genes, Leloir pathway genes, lactose-specific IIA & IIBC component encoding genes (lacF2 and lacE2), and the lacT gene, encoding a transcriptional antiterminator. Conversely, we found down-regulation of glycolysis pathway genes in pyrimidinedione-grown biofilms. The up-regulation of galactose metabolism genes indicated that cellular carbohydrate metabolism was changed, and cells adapted to an alternative pathway. In pneumococci, the galactose and lactose metabolism pathway genes are up-regulated in the presence of sugars other than glucose [55]. The precise reason for the up-regulation of the galactose metabolic pathway genes in the presence of pyrimidinedione remains to be elucidated. However, it was reported that the transcription factor CcpA (carbon catabolite protein A), ptsH, encoding the phosphocarrier protein HPr, and the SPD_0082 gene, encoding a sensor histidine kinase, facilitates pneumococci utilization of diverse carbohydrate sources during colonization, multiplication, and biofilm formation [56,57]. Moreover, the regulation of the central carbohydrate metabolic pathway genes is under the control of carbon catabolite repression (CCR), which is mediated by the transcription factor CcpA and the histidine phosphoprotein HPr [58,59,60].

The down-regulation of five phosphate-specific transport system genes indicates that the transportation of molecules from the periplasm to the cytoplasm may be hindered by pyrimidinedione. Mutagenesis of the pst ABC genes in pneumococci resulted in decreased rates of phosphate uptake, decreased growth rates, decreased transformation, and reduced pathogenicity [61,62]. Here we detected the down regulation of virulence-related genes (ply, srtA, ptrA, lytB, nrc, and SPD_1295) in pyrimidinedione-grown biofilms. The ply gene is a virulence gene encoding the toxin pneumolysin, which causes eukaryotic cell lysis and plays a major role in pneumococcal invasion [63,64]. In S. pneumoniae, the srtA gene is another virulence gene, and the srtA gene mutant strain showed low virulence and low adherence towards human pharyngeal cells [65]. The lytB gene encodes a choline-binding protein, and nrc and SPD_1295 encode...
hemolytic proteins. The \textit{prtA} gene encodes the pneumococcal cell wall-associated serine protease A, which is important in virulence in intraperitoneal infections [66].

The significantly decreased biofilm growth observed in the presence of pyrimidinedione may be due to the decreased expression of competence and biofilm-related genes (Fig 13). Here, the competence stimulating peptide-1 (CSP-1) precursor encoding gene \textit{comC}, the two-component regulator encoding genes \textit{ciaH} and \textit{ciaR}, and the alternative sigma factor encoding gene \textit{comX} were down-regulated in response to pyrimidinedione treatment. In \textit{S. pneumoniae}, the CSP-mediated QS system initiates the regulation of genetic competence, which involves the expression of early gene products encoded by \textit{comAB} and \textit{comCD} genes, and the two-component regulatory system CiaH-CiaR [67,68]. The pneumococcal \textit{comC} gene encodes the CSP precursor and the \textit{comDE} genes encode the CSP receptor and response regulator protein. The CiaH-CiaR negatively regulates \textit{comCDE} expression and thus affects the development of competence. The response regulator comE binds to the early gene promoter and initiates transcription, as a results accumulation of CSP, ComD, phosphorylated ComE and ComX (a global transcription modulator) increases. The ComX alternative sigma factor initiates the transcription of late competence-specific operon, which facilities in DNA uptake and recombination of DNA [68,69]. Previous studies have reported that QS plays an important role in biofilm formation and a \textit{ciaR/H} gene mutant strain was unable to form biofilms [49]. Oggioni et al. (2006)
detected up-regulation of the \textit{comC} gene in biofilms and demonstrated that \textit{S. pneumoniae} \textit{comC} mutants were less virulent and unable to form biofilms \textit{in vitro}. They further reported that, when supplemented with external CSP-1, wild type levels of biofilm formation were restored in the mutant strain [18]. Similarly, in \textit{S. mutans}, a \textit{comC} mutant strain was unable to produce the signal peptide and biofilm formation was disrupted.

Our results indicate that the Dam inhibitor, pyrimidinedione, down-regulates the expression of various pathway genes including those involved in cellular metabolism, translation, transcription, cell division, amino-acid synthesis, virulence, and DNA replication. Previous

\textbf{Fig 13. Schematic diagram representing genetic competence mediated by quorum sensing molecule competence specific peptide (CSP) in S. pneumoniae.} Induction of genetic competence in pneumococci is regulated by a CSP–mediated quorum-sensing system. The precursor of CSP is encoded by the \textit{comC} gene, and the ComAB (secretary and transporter) protein, facilitates extracellular accumulation of mature CSP. Mature CSP then binds to ComD receptor, resulting in ComD auto-phosphorylation and phosphoryl group transfer to the response regulator, ComE. Phosphorylated ComE binds to the early gene promoter and activates the transcription of early genes. As a result of ComE binding, the transcription of the \textit{comCDE} operon, and the production of CSP, ComD and phosphorylated ComE levels increase. ComE binding also initiates the accumulation of ComX (alternative sigma factor). ComX binds to the late gene promoter and stimulates the expression of late protein-encoding genes which facilitates recombination and DNA uptake. CiaH-CiaR is the second two-component regulatory system affecting the development of competence via regulation of \textit{comCDE} expression. The fold-changes of gene expression are highlighted in red.

doi:10.1371/journal.pone.0139238.g013
studies report that disruption of Dam or Dam activity affects bacterial fitness and alters gene expression [39,40,41,70]. These perturbations were postulated to be indirect secondary effects of basic cellular fitness. As a result, pneumococcal planktonic cell growth was reduced but not completely inhibited. It is likely that the down-regulation of competence and biofilm-related genes resulted in lower levels of biofilm growth. These bacteria were unable to build organized biofilms or aggregate biofilm matrix [49].

**Conclusion**

This study demonstrated that a small molecule Dam inhibitor, pyrimidinedione, perturbed pneumococcal biofilm growth in vitro at concentrations that did not inhibit planktonic cell growth and down-regulated the expression of important metabolic-, virulence-, competence-, and biofilm-related genes. Pyrimidinedione is also effective against MSSA, MRSA, and *Staphylococcus epidermidis* biofilm growth in vitro, and it is not cytotoxic to mammalian cells. Pyrimidinedione has potential for the development of new anti-biofilm compounds, and a ideal candidate molecule which require further study for in vivo biofilm prevention.

**Acknowledgments**

The authors thank Dr. Hee-bok Kim, Department of Otorhinolaryngology-Head and Neck Surgery, Dongguk University Ilsan Hospital for help with SEM.

**Author Contributions**

Conceived and designed the experiments: MKY JJS. Performed the experiments: MKY YYG. Analyzed the data: MKY JJS YYG SWC. Contributed reagents/materials/analysis tools: MKY JJS YYG SWC. Wrote the paper: MKY JJS YYG SWC.

**References**

1. Jedrzejas MJ. Pneumococcal Virulence Factors: Structure and Function. Microbiol Mol Biol Rev. 2001; 65: 187–207. PMID: 11381099
2. Klugman KP, Madhi SA, Albrich WC. Novel Approaches to the Identification of *Streptococcus pneumoniae* as the Cause of Community-Acquired Pneumonia. Clin Infect Dis. 2008; 47: S202–S206. doi: 10.1086/591405 PMID: 18986290
3. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet. 2008; 374: 1543–1556. doi: 10.1016/S0140-6736(09)61114-4 PMID: 19880020
4. Bogaert D, van Belkum A, Sluijter M, Luijendijk A, de Groot R, Rümke HC, et al. Colonisation by *Streptococcus pneumoniae* and *Staphylococcus aureus* in healthy children. Lancet. 2004; 363: 1871–1872. PMID: 15183627
5. Simell B, Auranen K, Käyhty H, Goldblatt D, Dagan R, O’Brien KL, et al. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines. 2012; 11: 841–855. PMID: 22913260
6. Hall-Stoodley L, Hu FZ, Gieseke A, Nistico L, Nguyen D, Hayes J, et al. Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. JAMA 2006; 296: 202–211. PMID: 16835426
7. Sanchez CJ, Shishshankar P, Stol K, Trakhtenbroit S, Sullam PM, Sauer K, et al. The Pneumococcal Serine-Rich Repeat Protein Is an Intra-Species Bacterial Adhesin That Promotes Bacterial Aggregation In Vivo and in Biofilms. PLoS Pathog. 2010; 6: e1001044. doi: 10.1371/journal.ppat.1001044 PMID: 20714350
8. Weimer KED, Armbruster CE, Juneau RA, Hong W, Pang B, Swords WE, et al. Coinfection with *Haemophilus influenzae* Promotes Pneumococcal Biofilm Formation during Experimental Otitis Media and Impedes the Progression of Pneumococcal Disease. J Infect Dis. 2010; 202: 1068–1075. doi: 10.1086/656046 PMID: 20715928
9. Ash SY, Sheffield JVL. Pneumococcus. Med Clin North Ame 2013; 97: 647–666.
10. Pichichero ME. Otitis Media. Pediatr Clin North Ame. 2013; 60: 391–407.
11. Shak JR, Vidal JE, Klugman KP. Influence of bacterial interactions on pneumococcal colonization of the nasopharynx. Trends Microbiol. 2013; 21: 129–135. doi: 10.1016/j.tim.2012.11.005 PMID: 23273566

12. Costerton JW, Stewart P, Greenberg E. Bacterial biofilms: a common cause of persistent infections. Science. 1999; 284: 1318–1322. PMID: 10334980

13. Kania RE, Lamers GEM, Vonk MJ, Dorp mans E, Struik J, Tran Huy P, et al. Characterization of Muco- Sal biofilms on Human Adenoid Tissues. Laryngoscope. 2008; 118: 128–134. PMID: 17975509

14. Vlastarakos PV, Nikolopoulos TP, Maragoudakis A, Tzagarakakis A, Ferekidis E. Biofilms in Ear, Nose, and Throat Infections: How Important are They? Laryngoscope. 2007; 117: 668–673. PMID: 17415138

15. del Prado G, Ruiz V, Naves P, Rodríguez-Cerrato V, Soriano F, del Carmen Ponte M, et al. Biofilm formation by Streptococcus pneumoniae strains and effects of human serum albumin, ibuprofen, N-acetyl-l-cysteine, amoxicillin, erythromycin, and levofloxacin. Diagn Microbiol Infect Dis. 2010; 67: 311–318. doi: 10.1016/j.diagmicrobio.2010.03.016 PMID: 20638597

16. García-Castillo M, Morosini MI, Valverde A, Almaraz F, Baquero F, Cantón R, et al. Differences in biofilm development and antibiotic susceptibility among Streptococcus pneumoniae isolates from cystic fibrosis samples and blood cultures. J Antimicrob Chemother. 2007; 59: 301–304. PMID: 17142818

17. Marks LR, Parameswaran GI, Hakansson AP. Pneumococcal Interactions with Epithelial Cells Are Crucial for Optimal Biofilm Formation and Colonization In Vitro and In Vivo. Infect Immun. 2012; 80: 2744–2760. doi: 10.1128/IAI.00488-12 PMID: 22645283

18. Oggioni M, Trappetti C, Kadioglu A, Cassone M, Iannelli F, Ricci S, et al. Switch from planktonic to sessile life: a major event in pneumococcal pathogenesis. Mol Microbiol. 2006; 61: 1196–1210. PMID: 16925554

19. Martin CA, Hoven AD, Cook AM. Therapeutic frontiers: preventing and treating infectious diseases by inhibiting bacterial quorum sensing. Euro J Clin Microbiol Infect Dis. 2008; 27: 635–642.

20. Talekar SJ, Chochua S, Nelson K, Klugman KP, Quave CL, Vidal JE, et al. 220D-F2 from Rubus ulmifolius Kills Streptococcus pneumoniae Planktonic Cells and Pneumococcal Biofilms. PLoS ONE. 2014; 9: e97314. doi: 10.1371/journal.pone.0097314 PMID: 24823499

21. Yadav MK, Chae S-W, Im GJ, Chung J-W, Song J-J. Eugenol: A Phyto-Compound Effective against Methicillin-Resistant and Methicillin-Sensitive Staphylococcus aureus Clinical Strain Biofilms. PLoS ONE. 2015; 10: e0119564. doi: 10.1371/journal.pone.0119564 PMID: 25781975

22. Reisenauer A, Kahng LS, McCollum S, Shapiro L. Bacterial DNA Methylation: a Cell Cycle Regulator? J Bacteriol. 1999; 181: 5135–5139. PMID: 10464180

23. Garcia-Del Portillo F, Pucciarelli MG, Casadesús J. DNA adenine methylase mutants of Salmonella typhimurium show defects in protein secretion, cell invasion, and M cell cytotoxicity. Proceedings of the National Academy of Sciences. 1999; 96: 11578–11583.

24. Heithoff DM, Sinzheimer RL, Low DA, Mahan MJ. An Essential Role for DNA Adenine Methylation in Bacterial Virulence. Science. 1999; 284: 967–970. PMID: 10320378

25. Cornell KA, Primus S, Martinez JA, Parveen N. Assessment of methylthioadenosine/S-adenosylhomocysteine nucleosidases of Borrelia burgdorferi as targets for novel antimicrobials using a novel high-throughput method. J Antimicrob Chemother. 2009; 63: 1163–1172. doi: 10.1093/jac/dkp129 PMID: 19376840

26. Parveen N, Cornell KA. Methylthioadenosine/S-adenosylhomocysteine nucleosidase, a critical enzyme for bacterial metabolism. Mole Microbiol. 2011; 79: 7–20.

27. Yadav MK, Chae S-W, Song J-J. Effect of 5–azacytidine on in vitro biofilm formation of Streptococcus pneumoniae. Microb Pathog. 2012; 53: 219–226. doi: 10.1016/j.micpath.2012.08.003 PMID: 22963864

28. Yadav MK, Park S-W, Chae S-W, Song J-J. Sinefungin, a Natural Nucleoside Analogue of S-Adenosylmethionine, Inhibits Streptococcus pneumoniae Biofilm Growth. BioMed Res Int. 2014; 2014: 156987. doi: 10.1155/2014/156987 PMID: 25050323

29. Maslowsk N, Pruss C, Carroll M, Johnson PH, Reich NO. Selective Inhibitors of Bacterial DNA Adenine Methyltransferases. J Biomol Screen. 2006; 11: 497–510.

30. Baldassarri L, Creti R, Recchia S, Imperi M, Facinelli B, Giovanetti E, et al. Therapeutic Failures of Antibiotics Used To Treat Macrolide-Susceptible Streptococcus pyogenes Infections May Be Due to Biofilm Formation. J Clin Microbiol. 2006; 44: 2721–2727. PMID: 16991483

31. Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method. Methods. 2001; 25: 402–408. PMID: 11846609
32. Chun YM, Moon SK, Brackmann DE, Lee HY, Rhim JS, Webster P, et al. Immortalization of normal adult human middle ear epithelial cells using a retrovirus containing the E6/E7 genes of human papillomavirus type 16. Ann Otol Rhinol Laryngol. 2002; 111: 507–517. PMID: 12090706

33. Song J-J, Lee JD, Lee BD, Chae SW, Park MK. Effect of diesel exhaust particles on human middle ear epithelial cells. Int J Pediatr Otorhinolaryngology. 2012; 76: 334–338.

34. Allegrucci M, Sauer K. Formation of Streptococcus pneumoniae non-phase variable colony variants is due to increased mutation frequency present under biofilm growth conditions. J. Bacteriol. 2008; 190: 6330–6339. doi: 10.1128/JB.00707-08 PMID: 18658260

35. Rybtke MT, Jensen PO, Hoiby N, Givskov M, Tolker-Nielsen T, Bjarnsholt T. The implication of Pseudomonas aeruginosa biofilms in infections. Inflamm Allergy Drug Targets. 2011; 10: 141–157. PMID: 21231623

36. Beeeston AI, Surette MG. pfs-dependent regulation of autoinducer 2 production in Salmonella enterica serovar Typhimurium. J. Bacteriol. 2002; 184:3450–3456. PMID:12057938

37. Bassler BL, Greeberg EP, Stevens AM. Cross-species induction of luminescence in the quorum sensing bacterium Vibrio harveyi. J. Bacteriol 1997; 179: 4043–4045. PMID:9190823

38. Markham GD, Pajares MA. Structure-function relationship in methionine adenosyltransferases. Cell Mol Life Sci. 2009; 66:636–648. doi:10.1007/s00018-008-8516-1 PMID: 18953685

39. Heusipp G, Fälker S, Alexander Schmidt M. DNA adenine methylation and bacterial pathogenesis. Int J Med Microbiol. 2007; 297: 1–7. PMID: 17126598

40. Low DA, Weyand NJ, Mahan MJ. Roles of DNA Adenine Methylation in Regulating Bacterial Gene Expression and Virulence. Infect Immun. 2004; 53: 651–664. PMID:15228541

41. Marinus MG, Casadesus J. Roles of DNA adenine methylation in host–pathogen interactions: mismatch repair, transcriptional regulation, and more. FEMS Microbiol Rev. 2009; 33: 488–503. doi: 10.1111/j.1574-6976.2008.00159.x PMID: 19175412

42. Falkor S, Schmidt MA, Heusipp G. DNA methylation in Yersinia enterocolitica: role of the DNA adenine methyltransferase in mismatch repair and regulation of virulence factors. Microbiol. 2005; 151: 2291–2299.

43. Watson ME Jr, Jarisch J, Smith AL. Inactivation of deoxyadenosinemethyltransferase (dam) attenuates Haemophilus influenzae virulence. Mol. Microbiol. 2004; 53: 651–664. PMID:15228541

44. Lizcano A, Chin T, Sauer K, Tuomanen EJ, Orihuela CJ. Early biofilm formation on microtiter plates is not correlated with the invasive disease potential of Streptococcus pneumoniae. Microb Pathog. 2010; 48: 124–130. doi: 10.1016/j.micpath.2010.01.002 PMID: 20996771

45. Koopman JA, Marshall JM, Bhatiya A, Equale T, Kwiek JJ, Gunn JS. Inhibition of Salmonella enterica Biofilm Formation Using Small-Molecule Adenosine Mimetics. Antimicrob Agents Chemother. 2015; 59: 76–84. doi: 10.1128/AAC.01393-12 PMID: 25313216

46. Moscoso M, García E, López R. Biofilm Formation by Streptococcus pneumoniae: Role of Choline, Extracellular DNA, and Capsular Polysaccharide in Microbial Accretion. J Bacteriol. 2006; 188: 7785–7795. PMID:16936041

47. Whitchurch C, Tolker-Nielsen T, Ragas P, Mattick J. Extracellular DNA required for bacterial biofilm formation. Science. 2002; 295: 1487. PMID:11859186

48. Donlan R, Costerton J. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002; 15: 167–193. PMID:11932229

49. Trappetti C, Ogunniyi AD, Oggioni MR, Paton JC. Extracellular Matrix Formation Enhances the Ability of Streptococcus pneumoniae to Cause Invasive Disease. PLoS ONE. 2011; 6: e19844. doi:10.1371/journal.pone.0019844 PMID: 21611130

50. Orihuela CJ, Radin JN, Sublett JE, Gao G, Kaushal D, Tuomanen EJ. Microarray Analysis of Pneumococcal Gene Expression during Invasive Disease. Infect Immun. 2004; 72: 5582–5596. PMID: 15385455

51. Lu Y-J, Rock CO. Transcriptional regulation of fatty acid biosynthesis in Streptococcus pneumoniae. Mol Microbiol. 2006; 59: 551–566. PMID: 16390449

52. Ajdić D, Ferretti JJ. Transcriptional Regulation of the Streptococcus mutans gal Operon by the GaI-R Repressor. J Bacteriol. 1998; 180: 5727–5732. PMID: 9791125

53. Fridovich-Keil JL. Galactosemia: The good, the bad, and the unknown. J Cell Physiol. 2006; 209: 701–705. PMID: 17001680

54. Zeng L, Martino NC, Burne RA. Two Gene Clusters Coordinate Galactose and Lactose Metabolism in Streptococcus gordonii. Appl Environ Microbiol. 2012; 78: 5597–5605. doi: 10.1128/AEM.01393-12 PMID: 22660715
55. Afzal M, Shafeeq S, Kuipers OP. LacR Is a Repressor of lacABCD and LacT Is an Activator of lacTFEG, Constituting the lac Gene Cluster in Streptococcus pneumoniae. Appl Environ Microbiol. 2014; 80: 5349–5358. doi:10.1128/AEM.01370-14 PMID:24951784

56. Iyer R, Baliga NS, Camilli A. Catabolite Control Protein A (CcpA) Contributes to Virulence and Regulation of Sugar Metabolism in Streptococcus pneumoniae. J Bacteriol. 2005; 187: 8340–8349. PMID:16321938

57. Wen ZT, Burne RA. Functional Genomics Approach to Identifying Genes Required for Biofilm Development by Streptococcus mutans. Appl Environ Microbiol. 2002; 68: 1196–1203. PMID:11872468

58. Chauvaux S. CcpA and HPr (ser-P): mediators of catabolite repression in Bacillus subtilis. Res Microbiol. 1996; 147: 518–522. PMID:9084764

59. Gorke B, Stulke J. Carbon catabolite repression in bacteria: many ways to make the most out of nutrients. Nat Rev Micro. 2008; 6: 613–624.

60. Henkin TM, Grundy FJ, Nicholson WL, Chambliss GH. Catabolite repression of α amylase gene expression in Bacillus subtilis involves a trans-acting gene product homologous to the Escherichia coli lacI and galR repressors. Mol Microbiol. 1991; 5: 575–584. PMID:1904524

61. Novak R, Cauwels A, Charpentier E, Tuomanen E. Identification of a Streptococcus pneumoniae Gene Locus Encoding Proteins of an ABC Phosphate Transporter and a Two-Component Regulatory System. J Bacteriol. 1999; 181: 1126–1133. PMID:9973337

62. Polissi A, Pontiggia A, Feger G, Altieri M, Ferrari L, et al. Large-Scale Identification of Virulence Genes fromStreptococcus pneumoniae. Infect Immun. 1998; 66: 5620–5629. PMID:9826334

63. Hirst RA, Kadioglu A, O’Callaghan C, Andrew PW. The role of pneumolysin in pneumococcal pneumonia and meningitis. Clin Exp Immunol. 2004; 138: 195–201. PMID:15498026

64. Sakai F, Talekar SJ, Klugman KP, Vidal JE, for the Investigators G. Expression of Streptococcus pneumoniae Virulence-Related Genes in the Nasopharynx of Healthy Children. PLoS ONE. 2013; 8: e67147. PMID:23825636

65. Paterson GK, Mitchell TJ. The role of Streptococcus pneumoniae sortase A in colonisation and pathogenesis. Microbes Infect. 2006; 8: 145–153. PMID:16182588

66. Bethe G, Nau R, Wellmer A, Hakenbeck R, Heinzel H-P, et al. The cell wall-associated serine protease PrtA: a highly conserved virulence factor of Streptococcus pneumoniae. FEMS Microbiol Lett. 2001; 205: 99–104. PMID:11728722

67. Kleerebezem M, Quadri LEN, Kuipers OP, De Vos WM. Quorum sensing by peptide pheromones and two-component signal-transduction systems in Gram-positive bacteria. Mol Microbiol. 1997; 24: 895–904. PMID:9219999

68. Lee MS, Morrison DA. Identification of a New Regulator inStreptococcus pneumoniae Linking Quorum Sensing to Competence for Genetic Transformation. J Bacteriol. 1999; 181: 5004–5016. PMID:10438773

69. Luo P, Morrison DA. Transient Association of an Alternative Sigma Factor, ComX, with RNA Polymerase during the Period of Competence for Genetic Transformation in Streptococcus pneumoniae. J Bacteriol. 2003; 185: 349–358. PMID:12486073

70. Løbner-Olesen A, Skovgaard O, Marinus MG. Dam methylation: coordinating cellular processes. Curr Opin Microbiol. 2005; 8: 154–160. PMID:15802246